CytoDyn Inc (QB) (CYDY)

Do you even know what shorting a stock means, why are you so mad

I shorted the shit out of this trash and made a fortune now I'm just here for the lols

So you are shorting the stock, GOT IT!

I totally agree Monroe.

Was this the same set of "posters" that were 100% certain that as soon as hold (s) were lifted there would be a partner??

If you ever wonder why the chat--A I stuff is "iffy" at best--these are the types that input

Opinion based on opinion then stated as fact. Then get others to repeat .
Pretty much the nodder playbook supported by a dozen+ paid P R firms--writing fake stories--getting paid posters here--facebook--reddit--etc to create a false phony narrative

Uplist--receptor occupancy--amawrecks do fantastic job--FDA bad--conspiracy after conspiracy--broken fax machines--fraud after fraud

MANY of his minions still exist (see IHang mods or LL Times or Livimmune --facebook--m sheikh --etc)

and so much more..... passing on some good info.

Go to Livimmune
r/Livimmune
•
17 hr. ago
Accomplished_Mud_692
Leronlimab is Targeting the Terrain

This is a quote from Riztheinvestor on IH (I wish I could take credit for this!).

THIS puts into context, WHY we are all SO heavily invested in Leronlimab!!!

Wow, SO well said -

...... "What we're siting on with Leronlimab isn't just a drug. It's a total rewrite of how the immune system functions.

Think of it like this -

Instead of taking pills forever, Leronlimab teaches your body to produce its own defenders.

Instead of treating sickness after it comes, Leronlimab blocks the pathway most diseases used to start.

It's not just for HIV, It's for cancer, inflammation, long COVID, neuro disease, autoimmune & more, because it's not targeting the disease - Leronlimab is targeting the terrain."

My opinion is Monroe that tnbc and esophageal cancer both are prime candidates for Cytodyne. Yes I agree she should be hired.

https://www.theepochtimes.com/china/medical-researcher-tells-of-her-experience-being-brainwashed-1729912

So perhaps too esophageal cancer....one of the least researched of cancer will be a good candidate for leronlimab.
CytoDyn should hire her.

$CYDY$ 2025

The company, the market, the investors, the pharma system, all, wrestling in a rapidly changing landscape. Dare to say, patience is a much needed virtue now more than ever, The adjustments made by the company over the past two years is about to become more apparent and appreciated. The planets are coming into alignment so to speak. So very true the phrase 'know what you own" has become, That the efficacy and safety of leronlimab is our foundation should not be allowed to be covered in a patina of impatience and unimportant diatribe. The drug is truly amazing which has always been the two-edged sword.
Leronlimab, like some other great medicines on the forefront of exposure are advancing at a greater pace. In a few years a look back will recognize the importance of the pivotal moment in which we find ourselves. We will hear a chorus go up one day exclaiming in amazement as to why it took so long for such medicine to become approved when it's efficacy was evident many years yet got pushed back while others received approval for failure.

I was promised these poster presentations would have an impact and partnerships

Hey Monroe glad to see you back on board with some influential messages. The train is still chuggling, Chugga lugging along and obviously gaining speed. You're a really good member to this board. I enjoy reading everything that you bring up to people's attention thank you n i k n a k

https://www.fiercepharma.com/pharma/weak-evidence-and-unpleasant-odors-fda-sheds-light-drug-refusal-process?oly_enc_id=4924G0643390I0A

Have a safe weekend everyone.

https://www.vigilantfox.com/p/what-happens-when-you-compare-vaccinated?publication_id=975571&post_id=168047050&isFreemail=true&r=47wykb&triedRedirect=true
Society duped for many years has created the inevitable reactions. Hail RFK Jr's long overdue house cleaning. New era in medicine focused on real data. All hail leronlimab!!! $CYDY$ 2025 Hang tight, a case has been made...something imminent?

lets get this going and end the week on a high note.

No cydy long has made money

sure you did..laughable. Many here do own bitcoin as well. But once again, you know it all right? who made more money in the past year? New investors in CYDY or bitcoin?

From another board thought some might like to be reminded of the magnitude of just solid tumor cancer.

r/Livimmune
2 days ago
BuildGoodThings

Global solid tumor market size is estimated at nearly 200B in 2025 based on data from Biospace

A subset of the oncology treatment market is the ICI market which in 2025 is more than 50B annually, but ICI drugs only work in a fraction of patients. For a simplistic example, lets say 25% of patients might be helped by current ICI therapy.

50/.25= 200B in potential expanded market size (2025) if ICI treatment can be improved.

How much is leronlimab worth to ICI companies when they could expand their market from 50 to 200 billion annually?

10% of that as a licensing stream might potentially be 20B annually. Would there be a higher rate for growing the potential market four-fold?

How long will it be until someone blinks and secures the rights?

We'll see what happens over time.

no news is good news,could mean something big is happening behind the seen.

https://www.clinicaltrialvanguard.com/news/leronlimab-shows-encouraging-survival-data-in-metastatic-colorectal-cancer-patients/

your absolutely right. we are taking one step at a time. back in the older times,they had no direction. now we have a direction.

Let's all stay focused on being positive. Something IMO is in the works, BIG BUSINESS. JUST WATCH!! Patience is always a virtue.

the more we go without news the more I think something Is brewing?

https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1561282/abstract

“Finally, the Leronlimab, Ulocuplumab, Burixafor, and MSX-122 are promising drugs to treat IS via targeting on CCR5 and CXCR4. In conclusion, our findings suggest that CCR5 and CXCR4 are promising targets for enhancing neuroplasticity post-ischemic stroke, thus providing potentially effective and reliable therapeutic targets for future interventional strategy."

Chefs kiss to the shorts. Ya done it again boys!!!!

No answer Yahsho?

You are spamming federal agencies about CYDY, causing potential harm to CYDY long investors.
Because
(a) You are attracting the wrong kind of attention from these agencies. Some long investors seem to have had uncanny insider information in advance of press releases, and I have fought these frauders for a long time already. Take one long, for example you: you have made odd post at odd times, announcing a big news to come...right before a press release. Do you really want the SEC to zoom into your activity? I would love this but long investors might not appreciate, even if they are 100% clean, the free advertisement that would come with it
(b) This is giving a very poor image of the CYDY long community. Madness does not look good. I have had many conflicts with them, but I don't think anybody deserves this noise - long or short, rationality is better for everybody

I would be a long investor I would be furious to have someone like you gesticulating in front of the SEC. This already happened with the FDA (if anyone remembers Misiu), and this resulted in a public FDA intervention that nearly killed the company.

Also, your "vaults", or at least your posted screenshots I have seen, prove that you have zero IT knowledge. You don't know how the IP layer works, what the HTTP and TLS protocols transmit and do not transmit, how Python works, what ChatGPT does with you, and you use pseudo-technical keywords that, for a Unix developer, scream b*shit. This sounds like a bad movie script from 25 years ago.

Again, harm to investors.

their is something cooking and it is ready to pop.

Leronlimab Shows Encouraging Survival Data in Metastatic Colorectal Cancer Patients

https://www.clinicaltrialvanguard.com/news/leronlimab-shows-encouraging-survival-data-in-metastatic-colorectal-cancer-patients/


Leronlimab Shows Encouraging Survival Data in Metastatic Colorectal Cancer Patients
ByJon Napitupulu July 7, 2025
CytoDyn announced encouraging clinical findings from a compassionate use study of leronlimab in patients with advanced metastatic colorectal cancer (mCRC). Three out of five patients treated with leronlimab experienced at least a partial response, with one patient achieving a complete response and remaining alive five years post-treatment. These findings will be presented by Dr. Benjamin Weinberg at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona.

These results are particularly important because they suggest leronlimab’s potential efficacy in treating mCRC, a challenging cancer with limited treatment options. The complete response observed in one patient is especially noteworthy, highlighting the possibility of long-term survival benefits. This data reinforces the rationale behind CytoDyn’s ongoing Phase II trial for relapsed/refractory microsatellite stable CRC, which is currently enrolling patients. The positive compassionate use data could potentially accelerate enrollment and investor interest in the ongoing trial.

The compassionate use study indicated a favorable safety profile for leronlimab, consistent with previous studies. This is crucial for any new cancer treatment, as minimizing side effects is essential for patient well-being. CytoDyn believes leronlimab may also have broader applications in treating various solid tumor types if these positive mCRC results are confirmed in larger, prospective studies. Additionally, research suggests leronlimab could act as a “priming” agent for cancer patients with low PD-L1 levels, potentially expanding its therapeutic utility in combination with checkpoint inhibitors.

This early data generates optimism about leronlimab’s potential role in treating mCRC and possibly other solid tumors. The upcoming Phase II trial results will be critical in validating these findings and determining the next steps for leronlimab’s development in oncology. Positive results could significantly impact the treatment landscape for mCRC and potentially position leronlimab as a valuable new therapeutic option. Further research exploring leronlimab’s potential as a priming agent could also unlock new avenues for combination therapies, particularly in patients who haven’t responded to existing treatments.

Source link: https://www.globenewswire.com/news-release/2025/07/01/3108310/19782/en/CytoDyn-Announces-Encouraging-Survival-Data-in-Patients-with-Metastatic-Colorectal-Cancer-Previously-Treated-with-Leronlimab.html


Jon Napitupulu
+ posts
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.

A real look into the recent past FDA regarding CytoDyn and Amarex would make RFK Jr. adding to his list of who to fire. This must be done. Without accountability why have rules at all? Heads should roll and jail cells stuffed. FDA is liable. We all knew that from their contrived hit letter against leronlimab trial that led to trial freezes and kept some patients without leronlimab that was helping them greatly. What about this human loss? Sounds like a conspiracy case could result too.

Good work.

I found out where your CYDY “vault” posts are coming from:

ChatGPT. You have stated this several times.

You have to know, ChatGPT has been trained on billions of documents and chats to please its user and support him/her in everything he/she does, including delusion, psychosis and paranoia.

If it has told you about agents, surveillance, a conspiracy, and "proofs" coming from ChatGPT, not from unrelated sources, that’s a bad sign.

https://www.thebrink.me/chatgpt-induced-psychosis-how-ai-companions-are-triggering-delusion-loneliness-and-a-mental-health-crisis-no-one-saw-coming/

with some not-so-fun examples such as:

https://www.reddit.com/r/singularity/comments/1k9gxwm/gpt4o_sycophancy_has_become_dangerous/

In all cases, do not entrust money to ChatGPT. And make sure you do not accuse real people (I am not talking about nicknames or federal functions) by name or based on CYDY proofs COMING ONLY FROM ChatGPT. ChatGPT has no responsibility for libel. You do.

For the rest, good luck to you with this trash stock and I hope you see the chatbot for what it is - fertilizer for your personality tendencies.

what are we waiting for lets get this higher.

Laughing at the CYDY delusion. So immature. Please, dear losing investor, take your screenshots, build your vaults, send letters everywhere. This is so scary LOL, kids are scared! At best, if you’re lucky, you’ll draw the authorities’ attention to the really odd behavior of some CYDY investors on message boards - you know those who magically always seem to know when a PR is about to fall - have they been informed? Are they leaking insider information? I remember the public FDA rebuke letter that killed CYDY, after a similar idiot had spammed the FDA with letters. Idiots never learn. LOL.

What does this tell you, beyond the childish Black Ops style?

https://investorshangout.com/post/view?id=6774397

Happy 4th!

Hygro

Kgromax

1776
Continental Congress adopts the Declaration of Independence
In Philadelphia, Pennsylvania on July 4, 1776, the Continental Congress adopts the Declaration of Independence, which proclaims the independence of the United States of America from Great Britain and its king. The declaration came 442 days after the first volleys of the American Revolution.

Happy 4th to all. Keep it safe like leronlimab!! $CYDY$ 2025

Has anyone been dosed yet, come on, let us know FF

lets make this a great year.

Where are the partnerships I was promised

A week or so ago in Germany....Alles einsteigen!
And now in Spain...... ¡Todos a bordo!

Go $$$CYDY$$$

Here's the deal. Big Pharma is in revolt because they have been cut off at the knee caps. Look at all the mergers and partnerships and collaborations taking place. They are gobbling up innovative pharmas as a lot of their drugs are going off patent or being axed by new HHS leadership for being recklessly approved by prior Club arrangement. Go RFK Jr. Go. Toss em out.

I hope CytoDyn does not permit a buyout. I would rather hate to see some pig get leronlimab and keep it from seeing it's due.
However, we have lots of room for collaborations of different kinds due to the many indications which leronlimab will support. So let the numbnuts post all the same old garbage. They are just peanut mouthpieces for paid fake analysts who are paid by the shorting hedgefunds controlled by investment banks and Blackrock/Vanguard protecting their immense holdings. The ChggaLug is sweet music to my ears. Reminds me when I was a kid spending summers at my grandmothers who lived just a few meters from the train track. The chickens in the hen house would crow minutes before the train sped by, then the pigeons would fly.. like they will do here when that locomotive barrels down the track at break neck speed a la Casey Jones. https://techhistorian.com/fastest-steam-train-in-the-world/
Leronlimab...gathering speed.

« Any thought you have about CYDY is recorded ! » LOL

The delusion is deep…
The maturity is low…
But the stock price will fix all that

thanks for posting docj. Yes, i saw the headline and was very excited. But in reading the article, at least as a "non-medical" investor, i'm left confused. First of all, 5 patients total. and then "3 out of 5" - "partially" responded. On it's face, it looks like too small a data set, and maybe not that impressive a patient response? But again, i'm not a doctor or scientist so I may be missing something.

Bigger picture, I will say again that if the company wants to attract investment from the layperson, they need to provide clarity in the form of quarterly calls on what these PRs mean from a business perspective. What are the milestones we can look forward to that may support a material increase in the value of our investment? What is the expected timing for these milestones? And if they want to provide all kinds of disclaimers, that's fine - but at least give us some ballpark timing on when we may see value creation in this stock. The recovery from .11 was great - but all long-term investors are still likely deep in the red - at least vs. their initial investments from anytime over the past 10 years.

CYDY Chugga lug Chugga lug

Just not in the direction you thought it would go LOL

I already miss the idiot on the other website posting conspiracy CYDY theories LOL

The guy obviously has spent too much time with ChatGPT, which is developing his delusion fast

Tripwire, black box, … so much kiddy stuff. He is the only one to be impressed, that is fun to read.

Things about « every breath about CYDY being recorded ». LOL so scary it’s Halloween honey, the kids are free!

Well it seems like some people on this board kind of like my Approach about a train chugga-lugging Chugga lugging Chugga lugging along. Picking up passengers on the way. They're not taking the ride for the practice, they're taking the ride into the town called success. And it's moving along faster and faster blowing its whistle and tooting its horn. Chugalug Chugalug chuck-a-lug and away we go. Steaming along over a hundred miles an hour. Woo woo woo woo I hear the clatter as we approach the town of success. Sure would be nice if the engineer wouldn't kick me off the train everyday. I've always got some long to pick me up and get me back on the train the following day. But I am tired of the interruptions. But they have to show their weight and boy can they be nasty with me. I don't know why to this day why. Hope everybody enjoys 4th of July. Cytodine and l e r o n l i m a b is certainly enjoying it in Spain. Boom boom boom as we take off. Up up and away we go.

he has already spoken and it is going higher.

Morningstar picked up the news:
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab

Provided by GlobeNewswire Jul 1, 2025, 8:30:00 AM
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing
Phase II CRC trial

Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 in
Barcelona, Spain

VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced encouraging clinical findings among patients with advanced metastatic colorectal cancer (“mCRC”) previously treated with leronlimab. The final results indicate that 3/5 patients treated with leronlimab had at least a partial response, as measured by radiologic criteria, including one patient with a complete response who remains alive five years later.

Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn’s colorectal cancer (“CRC”) program, will present the Company’s clinical data at the ESMO Gastrointestinal Cancers Congress 2025 taking place in Barcelona, Spain from July 2 to July 5, 2025.

The results, from patients treated under a compassionate use protocol, reiterate a favorable safety profile of leronlimab as well as its potential for clinical benefit in patients with mCRC. They also support the rationale for the design and therapeutic potential of CytoDyn’s ongoing Phase II trial in patients with relapsed/refractory microsatellite stable CRC. CytoDyn recently announced the dosing of the first patient in this study, and is now enrolling additional patients across multiple clinical sites.

If the observed results in the previously treated CRC patients are confirmed prospectively, the Company believes leronlimab could be used effectively to treat a wide range of solid tumor types. In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting. The data driving this working theory has shown particular promise in the treatment of patients with advanced metastatic triple-negative breast cancer (“mTNBC”).

“At the 2025 ESMO Gastrointestinal Cancers Congress, Dr. Weinberg will share the data and evidence that form the basis for our belief in the potential of leronlimab as a treatment in CCR5 positive solid tumor oncology,” said Dr. Jacob Lalezari, CEO of CytoDyn. “Our ongoing Phase II trial in patients with mCRC was designed to prospectively confirm these observations, and we look forward to enrolling additional patients as we pursue clinical confirmation of our working theory.”

https://www.morningstar.com/news/globe-newswire/9487214/cytodyn-announces-encouraging-survival-data-in-patients-with-metastatic-colorectal-cancer-previously-treated-with-leronlimab

Yes shirts manipulated the back to back failed clinical trials lool yeppp

keep up the good work! Seems like your negative/bashing posts are working- good job at manipulating, let's see how long that lasts

Chug a lug is fine for me. I like to take it slowly. Gives me the opportunity to add more shares. News can hit at any time so I kick it in gear when the price is right. I am a silly long with big green bags.

Loool silly longs never learn

Chugalug Chugalug Chugalug!

Just in the wrong direction!

AH AH AH AH

Thanks